The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer’s […]readmore
Tags : Dova Pharmaceuticals
Shots: Sobi acquires Dova Pharmaceutical in cash & stock transaction making a total deal value as $915M. Dova to receive upfront of $27.50/share in cash, $1.50/share on approval of Doptelet […]readmore
Shots: Dova Pharmaceuticals to pay Salix Pharmaceuticals, a quarterly fee on the US sales. Salix to deploy ~100 specialists for promotion of Doptelet which is expected to launch in mid-Oct […]readmore